4.6 Review

Clinical and molecular complexity of breast cancer metastases

期刊

SEMINARS IN CANCER BIOLOGY
卷 35, 期 -, 页码 85-95

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2015.08.009

关键词

Breast cancer; Tumor heterogeneity; Metastasis; Organ-specific tropism; Prognosis; Targeted therapy

类别

资金

  1. Swedish Cancer Society
  2. Gunnar Nilsson Cancer Foundation
  3. Berta Kamprad Foundation
  4. Gyllenstierna Krapperup's Foundation
  5. King Gustaf V Jubilee Foundation
  6. BioCARE
  7. Swedish Cancer and Allergy Foundation
  8. governmental funding of clinical research within the National Health Services (ALF Region Skane)

向作者/读者索取更多资源

Clinical oncology is advancing toward a more personalized treatment orientation, making the need to understand the biology of metastasis increasingly acute. Dissecting the complex molecular, genetic and clinical phenotypes underlying the processes involved in the development of metastatic disease, which remains the principal cause of cancer-related deaths, could lead to the identification of more effective prognostication and targeted approaches to prevent and treat metastases. The past decade has witnessed significant progress in the field of cancer metastasis research. Clinical and technological milestones have been reached which have tremendously enriched our understanding of the complex pathways undertaken by primary tumors to progress into lethal metastases and how some of these processes might be amenable to therapy. The aim of this review article is to highlight the recent advances toward unraveling the clinical and molecular complexity of breast cancer metastases. We focus on genes mediating breast cancer metastases and organ:-specific tropism, and discuss gene signatures for prediction of metastatic disease. The challenges of translating this information into clinically applicable tools for improving the prognostication of the metastatic potential of a primary breast tumor, as well as for therapeutic interventions against latent and active metastatic disease are addressed. (C) 2015 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Common Susceptibility Loci for Male Breast Cancer

Sarah Maguire, Eleni Perraki, Katarzyna Tomczyk, Michael E. Jones, Olivia Fletcher, Matthew Pugh, Timothy Winter, Kyle Thompson, Rosie Cooke, Alison Trainer, Paul James, Stig Bojesen, Henrik Flyger, Heli Nevanlinna, Johanna Mattson, Eitan Friedman, Yael Laitman, Domenico Palli, Giovanna Masala, Ines Zanna, Laura Ottini, Valentina Silvestri, Antoinette Hollestelle, Maartje J. Hooning, Srdjan Novakovic, Mateja Krajc, Manuela Gago-Dominguez, Jose Esteban Castelao, Hakan Olsson, Ingrid Hedenfalk, Emmanouil Saloustros, Vasilios Georgoulias, Douglas F. Easton, Paul Pharoah, Alison M. Dunning, D. Timothy Bishop, Susan L. Neuhausen, Linda Steele, Alan Ashworth, Montserrat Garcia Closas, Richard Houlston, Anthony Swerdlow, Nick Orr

Summary: This study identified three new susceptibility loci for male breast cancer, revealing a shared genetic basis with female breast cancer, and men in the top quintile of genetic risk had a fourfold increased risk of breast cancer compared to those in the bottom quintile.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Article Oncology

High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer

Sara Corvigno, Artur Mezheyeuski, Laura Martin De La Fuente, Sofia Westbom-Freme, Joseph W. Carlson, Josefin Fernebro, Elisabeth Avall-Lundqvist, Paivi Kannisto, Ingrid Hedenfalk, Susanne Malander, Charlotte Rolny, Hanna Dahlstrand, Arne Ostman

GYNECOLOGIC ONCOLOGY (2020)

Article Multidisciplinary Sciences

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients

Pia Leandersson, Anna Akesson, Ingrid Hedenfalk, Susanne Malander, Christer Borgfeldt

PLOS ONE (2020)

Article Oncology

Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer

Jenny-Maria Jonsson, Maria Baath, Ida Bjornheden, Irem Durmaz Sahin, Anna Masback, Ingrid Hedenfalk

Summary: Serous endometrial cancer (SEC) is an aggressive subtype with similarities to high-grade serous ovarian cancer (HGSOC), potentially benefiting from targeted treatments like PARP inhibitors. A study revealed that some SEC patients have homologous recombination repair deficiency, indicating a possible targeted therapy approach.

CANCERS (2021)

Article Biochemistry & Molecular Biology

Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer

Maciej Ciesla, Phuong Cao Thi Ngoc, Eugenia Cordero, Alvaro Sejas Martinez, Mikkel Morsing, Sowndarya Muthukumar, Giulia Beneventi, Magdalena Madej, Roberto Munita, Terese Jonsson, Kristina Lovgren, Anna Ebbesson, Bjorn Nodin, Ingrid Hedenfalk, Karin Jirstrom, Johan Vallon-Christersson, Gabriella Honeth, Johan Staaf, Danny Incarnato, Kristian Pietras, Ana Bosch, Cristian Bellodi

Summary: The study uncovers the central role of the core splice factor SF3A3 in rewiring splicing during malignant transformation, particularly in the context of MYC hyperactivation. SF3A3 levels are modulated through translation in an elF3D-dependent manner, leading to metabolic reprogramming and stem-like properties that fuel MYC tumorigenic potential. Overall, these findings reveal a post-transcriptional interplay between splicing and translation that governs critical facets of MYC-driven oncogenesis.

MOLECULAR CELL (2021)

Article Genetics & Heredity

MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer

Maria Baath, Jenny-Maria Jonsson, Sofia Westbom Fremer, Laura Martin de la Fuente, Lena Tran, Susanne Malander, Paivi Kannisto, Anna Masback, Gabriella Honeth, Ingrid Hedenfalk

Summary: The study found that MET expression is associated with prognosis in high-grade serous ovarian cancer, especially in SOX2-negative tumors. In vitro experiments showed no synergistic effects of combined treatment with PARP and MET inhibitors in cell lines with BRCA1 or BRCA2 deficiencies.
Article Oncology

bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer

A. Matikas, K. Wang, E. Lagoudaki, B. Acs, I Zerdes, J. Hartman, E. Azavedo, J. Bjohle, L. Carlsson, Z. Einbeigi, I Hedenfalk, M. Hellstrom, T. Lekberg, N. Loman, A. Saracco, A. von Wachenfeldt, S. Rotstein, M. Bergqvist, J. Bergh, T. Hatschek, T. Foukakis

Summary: The study highlights the potential value of TK1 activity as a prognostic marker in breast cancer patients. Changes in TK1 activity during chemotherapy were closely associated with patient survival outcomes, improving event-free survival and overall survival rates.

ESMO OPEN (2021)

Article Oncology

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

Jane Bayani, Coralie Poncet, Cheryl Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schroder, Isabel T. Rubio, Kathryn J. Ruddy, Christi van Asperen, Danielle Van den Weyngaert, Carolien van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Sharon H. Giordano, Fatima Cardoso, John M. S. Bartlett

Summary: The gene expression results of male breast cancer patients in the study demonstrate clinical utility in risk assessment and significant differences in prognosis based on different risk scores.

NPJ BREAST CANCER (2021)

Article Oncology

RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer

Johan Staaf, Jari Hakkinen, Cecilia Hegardt, Lao H. Saal, Siker Kimbung, Ingrid Hedenfalk, Tonje Lien, Therese Sorlie, Bjorn Naume, Hege Russnes, Rachel Marcone, Ayyakkannu Ayyanan, Cathrin Brisken, Rebecka R. Malterling, Bengt Asking, Helena Olofsson, Henrik Lindman, Par-Ola Bendahl, Anna Ehinger, Christer Larsson, Niklas Loman, Lisa Ryden, Martin Malmberg, Ake Borg, Johan Vallon-Christersson

Summary: Using RNA-sequencing, single-sample predictor (SSP) models were developed for clinical markers, subtypes, and risk of recurrence. The results show high consistency between the SSP models and Prosigna in terms of subtypes and risk categories, as well as for chemotherapy recommendations.

NPJ BREAST CANCER (2022)

Article Oncology

How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer

Hani Saghir, Srinivas Veerla, Martin Malmberg, Lisa Ryden, Anna Ehinger, Lao H. Saal, Johan Vallon-Christersson, Ake Borg, Cecilia Hegardt, Christer Larsson, Alaa Haidar, Ingrid Hedenfalk, Niklas Loman, Siker Kimbung

Summary: This study aimed to assess the reliability of using CNB for preoperative tumor characterization in early breast cancer. Results showed moderate to very good correlation between IHC and GEX assessment in paired CNB and surgical specimens, with some discrepancies observed in Ki67 and ER across different techniques, potentially impacting treatment decisions and patient outcomes.

CANCERS (2022)

Article Biochemistry & Molecular Biology

A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer

Ahmad Nasimian, Mehreen Ahmed, Ingrid Hedenfalk, Julhash U. Kazi

Summary: In this study, a gene signature was defined through the analysis of cisplatin-perturbed gene expression and pathway enrichment, and a cisplatin sensitivity prediction model was developed using the TabNet algorithm. The TabNet model outperformed other machine learning models with an accuracy of over 80%. Furthermore, BCL2L1 was identified as an important gene contributing to cisplatin resistance, and its pharmacological inhibition was found to enhance cisplatin efficacy. This study developed a tool to predict cisplatin sensitivity and identified BCL2L1 as a significant gene in this context.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)

Article Oncology

CD169+ Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, Tregs and a Worse Prognosis for Patients with Advanced Breast Cancer

Oscar Briem, Eva Kallberg, Siker Kimbung, Srinivas Veerla, Jenny Stenstrom, Thomas Hatschek, Catharina Hagerling, Ingrid Hedenfalk, Karin Leandersson

Summary: We found that CD169(+) macrophages in primary breast tumors are associated with tertiary lymphoid-like structures (TLLSs), T-reg and B-reg signatures, and a worse prognosis for the patient. However, CD169(+) macrophages and TLLSs in lymph node metastases are associated with a better prognosis. We propose that the negative prognostic value of CD169(+) macrophages and TLLSs in primary breast tumors is a unique consequence of an immunosuppressive tumor environment in advanced breast cancers.

CANCERS (2023)

Article Oncology

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers

Mads H. Haugen, Ole Christian Lingjaerde, Ingrid Hedenfalk, Oystein Garred, Elin Borgen, Niklas Loman, Thomas Hatschek, Anne-Lise Borresen-Dale, Bjorn Naume, Gordon B. Mills, Gunhild M. Maelandsmo, Olav Engebraaten

Summary: In breast cancer patients, a nine-protein signature score named vascular endothelial growth factor inhibition response predictor (ViRP) was identified to predict the effectiveness of treatment with bevacizumab combined with chemotherapy, based on the expression levels of selected proteins. This ViRP score was internally validated on mRNA data and also validated in an independent phase II clinical trial, showing promise in predicting treatment benefit in HER2-negative breast cancer patients.

JCO PRECISION ONCOLOGY (2021)

Article Oncology

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Ake Borg, Alejandro Perez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth

Summary: Resistance to endocrine treatment in metastatic breast cancer poses a major clinical challenge, with complex mechanisms contributing to the development of diverse resistance patterns, impacting levels of estrogen receptor independence and potential cross-resistance to CDK inhibitors.

BREAST CANCER RESEARCH (2021)

Article Oncology

Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression

Jenny Stenstrom, Ingrid Hedenfalk, Catharina Hagerling

Summary: This study investigated the immune landscape in metastatic breast cancer patients, revealing that T lymphocytes and Tregs were the most clinically important immune cell populations in primary tumors. Infiltration of T lymphocytes and Tregs correlated with proliferation and estrogen receptor negativity, and T lymphocyte infiltration was an independent prognostic factor for recurrence-free survival while Treg infiltration was an independent prognostic factor for breast cancer-specific survival.

BREAST CANCER RESEARCH (2021)

暂无数据